Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 233 participants.

Also called NCT04365400

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 233 participants (enrolled count) (from the registry)
Sponsor
Afimmune (from the registry)
Registry
  • NCT NCT04365400
  • EudraCT 2020-000065-16
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Georgia, Germany, Israel, Latvia, Switzerland (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04365400. Randomized; double masking; primary purpose treatment. Start 2020-10-13 (actual); primary completion 2022-05-03 (actual). Results posted on 2023-06-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
Acronym
TRIAGE
Condition
Hypertriglyceridemia
Intervention (Drug)
DS102
Intervention (Drug)
Placebo
Lead sponsor
Afimmune (class: industry)

Record details

Record id
cardio:ct-nct04365400
Content hash
abef57b324f85366cf234e51dc8df8b101a28059d84b679b210e140bfc43f005